{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:40:06Z","timestamp":1795034406884,"version":"4.10.2"},"reference-count":95,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Dongguk University Research Fund of 2019","award":["S-2019-G0001-00009"],"award-info":[{"award-number":["S-2019-G0001-00009"]}],"id":[{"id":"https:\/\/ror.org\/057q6n778","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Cooperative Research Program for Agriculture Science &amp; Technology Development of Rural Development Administration in Republic of Korea","award":["Project No. PJ014297"],"award-info":[{"award-number":["Project No. PJ014297"]}],"id":[{"id":"https:\/\/ror.org\/03xs9yg50","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Tumor necrosis factor alpha (TNF-\u03b1) was initially recognized as a factor that causes the necrosis of tumors, but it has been recently identified to have additional important functions as a pathological component of autoimmune diseases. TNF-\u03b1 binds to two different receptors, which initiate signal transduction pathways. These pathways lead to various cellular responses, including cell survival, differentiation, and proliferation. However, the inappropriate or excessive activation of TNF-\u03b1 signaling is associated with chronic inflammation and can eventually lead to the development of pathological complications such as autoimmune diseases. Understanding of the TNF-\u03b1 signaling mechanism has been expanded and applied for the treatment of immune diseases, which has resulted in the development of effective therapeutic tools, including TNF-\u03b1 inhibitors. Currently, clinically approved TNF-\u03b1 inhibitors have shown noticeable potency in a variety of autoimmune diseases, and novel TNF-\u03b1 signaling inhibitors are being clinically evaluated. In this review, we briefly introduce the impact of TNF-\u03b1 signaling on autoimmune diseases and its inhibitors, which are used as therapeutic agents against autoimmune diseases.<\/jats:p>","DOI":"10.3390\/ijms22052719","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T12:12:18Z","timestamp":1615205538000},"page":"2719","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1660,"title":["The Role of Tumor Necrosis Factor Alpha (TNF-\u03b1) in Autoimmune Disease and Current TNF-\u03b1 Inhibitors in Therapeutics"],"prefix":"10.3390","volume":"22","author":[{"given":"Dan-in","family":"Jang","sequence":"first","affiliation":[{"name":"Department of Medical Biotechnology, Collage of Life Science and Biotechnology, Dongguk University, Seoul 04620, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0786-1482","authenticated-orcid":false,"given":"A-Hyeon","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnology, Collage of Life Science and Biotechnology, Dongguk University, Seoul 04620, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Yoon","family":"Shin","sequence":"additional","affiliation":[{"name":"School of Life Science, Handong Global University, Pohang, Gyeongbuk 37554, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4048-0411","authenticated-orcid":false,"given":"Hyo-Ryeong","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnology, Collage of Life Science and Biotechnology, Dongguk University, Seoul 04620, Korea"},{"name":"Department of Pharmacy, College of Pharmacy, Yonsei University, Seoul 03722, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Hwi","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnology, Collage of Life Science and Biotechnology, Dongguk University, Seoul 04620, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1441-9470","authenticated-orcid":false,"given":"Tae-Bong","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, College of Biomedical and Health Science, Konkuk University, Chungju 27478, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8672-301X","authenticated-orcid":false,"given":"Sang-Ryong","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Biological Environmental Science, Collage of Life Science and Biotechnology, Dongguk University, Seoul 04620, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6880-8861","authenticated-orcid":false,"given":"Seung-Hoon","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnology, Collage of Life Science and Biotechnology, Dongguk University, Seoul 04620, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/path.2287","article-title":"TNF-Mediated inflammatory disease","volume":"214","author":"Bradley","year":"2008","journal-title":"J. Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","article-title":"Transmembrane TNF-alpha: Structure, function and interaction with anti-TNF agents","volume":"49","author":"Horiuchi","year":"2010","journal-title":"Rheumatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/cdd.2016.162","article-title":"STAT1 mediates transmembrane TNF-alpha-induced formation of death-inducing signaling complex and apoptotic signaling via TNFR1","volume":"24","author":"Jiang","year":"2017","journal-title":"Cell Death Differ."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0962-8924(00)89088-1","article-title":"Two tumour necrosis factor receptors: Structure and function","volume":"5","author":"Vandenabeele","year":"1995","journal-title":"Trends Cell Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1056\/NEJM199606273342607","article-title":"The tumor necrosis factor ligand and receptor families","volume":"334","author":"Bazzoni","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/385729a0","article-title":"A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells","volume":"385","author":"Black","year":"1997","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/385733a0","article-title":"Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha","volume":"385","author":"Moss","year":"1997","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/0092-8674(95)90192-2","article-title":"The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor","volume":"83","author":"Grell","year":"1995","journal-title":"Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1002\/1529-0131(200112)44:12<2819::AID-ART469>3.0.CO;2-2","article-title":"Association of tumor necrosis factor receptor type II polymorphism 196R with Systemic lupus erythematosus in the Japanese: Molecular and functional analysis","volume":"44","author":"Morita","year":"2001","journal-title":"Arthritis Rheum."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"871","DOI":"10.4161\/cc.11.5.19300","article-title":"The role of TRADD in death receptor signaling","volume":"11","author":"Pobezinskaya","year":"2012","journal-title":"Cell Cycle"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nature14191","article-title":"Necroptosis and its role in inflammation","volume":"517","author":"Pasparakis","year":"2015","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nri3834","article-title":"Regulation of tumour necrosis factor signalling: Live or let die","volume":"15","author":"Brenner","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Holbrook, J., Lara-Reyna, S., Jarosz-Griffiths, H., and McDermott, M. (2019). Tumour necrosis factor signalling in health and disease. F1000Research, 8.","DOI":"10.12688\/f1000research.17023.1"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.molcel.2009.10.013","article-title":"Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction","volume":"36","author":"Haas","year":"2009","journal-title":"Mol. Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nature09816","article-title":"Linear ubiquitination prevents inflammation and regulates immune signalling","volume":"471","author":"Gerlach","year":"2011","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood-2011-04-325225","article-title":"Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey","volume":"119","author":"Aggarwal","year":"2012","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","article-title":"TNF biology, pathogenic mechanisms and emerging therapeutic strategies","volume":"12","author":"Kalliolias","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2008.03.036","article-title":"TNF-\u03b1 induces two distinct caspase-8 activation pathways","volume":"133","author":"Wang","year":"2008","journal-title":"Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/ni.1714","article-title":"Death receptor signal transducers: Nodes of coordination in immune signaling networks","volume":"10","author":"Wilson","year":"2009","journal-title":"Nat. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.cell.2009.05.037","article-title":"Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation","volume":"137","author":"Cho","year":"2009","journal-title":"Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.neuroscience.2015.06.038","article-title":"Tnf and Its Receptors in the Cns: The Essential, the Desirable and the Deleterious Effects","volume":"302","author":"Probert","year":"2015","journal-title":"Neuroscience"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","article-title":"Mechanisms of disease: Cytokine pathways and joint inflammation in rheumatoid arthritis","volume":"344","author":"Choy","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Adegbola, S.O., Sahnan, K., Warusavitarne, J., Hart, A., and Tozer, P. (2018). Anti-TNF Therapy in Crohn\u2019s Disease. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19082244"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1177\/0091270007301623","article-title":"The role of TNF alpha in ulcerative colitis","volume":"47","author":"Sands","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/ecco-jcc\/jjw053","article-title":"Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease","volume":"10","author":"Levin","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Celis, R., Cuervo, A., Ramirez, J., and Canete, J.D. (2019). Psoriatic Synovitis: Singularity and Potential Clinical Implications. Front. Med.-Lausanne, 6.","DOI":"10.3389\/fmed.2019.00014"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.5114\/aoms.2014.47827","article-title":"Tumor necrosis factor inhibitors\u2014State of knowledge","volume":"10","author":"Lis","year":"2014","journal-title":"Arch. Med. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4103\/0019-5154.53175","article-title":"Biologics: Target-specific treatment of systemic and cutaneous autoimmune diseases","volume":"54","author":"Raychaudhuri","year":"2009","journal-title":"Indian J. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3389\/fimmu.2018.00784","article-title":"Role of TNF-TNF Receptor 2 Signal in Regulatory T Cells and Its Therapeutic Implications","volume":"9","author":"Yang","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cytogfr.2014.07.016","article-title":"TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants\u2014Past, present and future","volume":"25","author":"Sedger","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Steeland, S., Libert, C., and Vandenbroucke, R.E. (2018). A New Venue of TNF Targeting. Int. J. Mol. Sci., 19.","DOI":"10.20944\/preprints201804.0015.v1"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41413-018-0016-9","article-title":"Rheumatoid arthritis: Pathological mechanisms and modern pharmacologic therapies","volume":"6","author":"Guo","year":"2018","journal-title":"Bone Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S0720-048X(98)00040-0","article-title":"Rheumatoid arthritis: Sequences","volume":"27","author":"Scutellari","year":"1998","journal-title":"Eur. J. Radiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.4049\/jimmunol.152.8.4149","article-title":"Vascular Endothelial Growth-Factor\u2014A Cytokine Modulating Endothelial Function in Rheumatoid-Arthritis","volume":"152","author":"Koch","year":"1994","journal-title":"J. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1146\/annurev.immunol.14.1.397","article-title":"Role of cytokines in rheumatoid arthritis","volume":"14","author":"Feldmann","year":"1996","journal-title":"Annu. Rev. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/00002281-200207000-00013","article-title":"Pathogenesis of bone erosions in rheumatoid arthritis","volume":"14","author":"Goldring","year":"2002","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Merola, J.F., Espinoza, L.R., and Fleischmann, R. (2018). Distinguishing rheumatoid arthritis from psoriatic arthritis. RMD Open, 4.","DOI":"10.1136\/rmdopen-2018-000656"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00296-007-0349-y","article-title":"Angiotensin-Converting enzyme gene polymorphism in patients with psoriatic arthritis","volume":"27","author":"Hasan","year":"2007","journal-title":"Rheumatol. Int."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic Arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/1346-8138.14139","article-title":"Pathogenesis of psoriasis and development of treatment","volume":"45","author":"Ogawa","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.4049\/jimmunol.175.4.2721","article-title":"TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques","volume":"175","author":"Gottlieb","year":"2005","journal-title":"J. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(07)60750-8","article-title":"Gastroenterology 1\u2014Inflammatory bowel disease: Cause and immunobiology","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(07)60751-X","article-title":"Gastroenterology 2\u2014Inflammatory bowel disease: Clinical aspects and established and evolving therapies","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/00054725-200411000-00015","article-title":"Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn\u2019s disease","volume":"10","author":"Ringheanu","year":"2004","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5217\/ir.2018.16.1.26","article-title":"Immunological pathogenesis of inflammatory bowel disease","volume":"16","author":"Lee","year":"2018","journal-title":"Intest. Res."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Rendon, A., and Schakel, K. (2019). Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061475"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Psoriasis 1\u2014Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41433-018-0223-z","article-title":"Noninfectious uveitis in the Asia-Pacific region","volume":"33","author":"Hsu","year":"2019","journal-title":"Eye"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.semarthrit.2019.06.004","article-title":"New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review","volume":"49","author":"Rosenbaum","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Leal, I., Rodrigues, F.B., Sousa, D.C., Duarte, G.S., Romao, V.C., Marques-Neves, C., Costa, J., and Fonseca, J.E. (2019). Anti-TNF Drugs for Chronic Uveitis in Adults-A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front. Med. Lausanne, 6.","DOI":"10.3389\/fmed.2019.00104"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.exer.2018.05.008","article-title":"The pathogenic role of dendritic cells in non-infectious anterior uveitis","volume":"173","author":"Fearon","year":"2018","journal-title":"Exp. Eye Res."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Gilbert, R.M., Zhang, X.Z., Sampson, R.D., Ehrenstein, M.R., Nguyen, D.X., Chaudhry, M., Mein, C., Mahmud, N., Galatowicz, G., and Tomkins-Netzer, O. (2018). Clinical Remission of Sight-Threatening Non-Infectious Uveitis Is Characterized by an Upregulation of Peripheral T-Regulatory Cell Polarized Towards T-bet and TIGIT. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00907"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ajo.2018.02.019","article-title":"Autoimmunity, Autoinflammation, and Infection in Uveitis","volume":"189","author":"Forrester","year":"2018","journal-title":"Am. J. Ophthalmol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/intimm\/dxu102","article-title":"Anti-TNF therapy: Past, present and future","volume":"27","author":"Monaco","year":"2015","journal-title":"Int. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: A comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1016\/S1590-8658(08)60530-7","article-title":"Mechanisms of action of infliximab in inflammatory bowel disease: An anti-inflammatory multitasker","volume":"40","author":"Danese","year":"2008","journal-title":"Dig. Liver Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/ajg.2011.27","article-title":"Mucosal Gene Expression of Cell Adhesion Molecules, Chemokines, and Chemokine Receptors in Patients with Inflammatory Bowel Disease Before and After Infliximab Treatment","volume":"106","author":"Arijs","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Guo, Y., Lu, N.H., and Bai, A.P. (2013). Clinical Use and Mechanisms of Infliximab Treatment on Inflammatory Bowel Disease: A Recent Update. Biomed. Res. Int., 2013.","DOI":"10.1155\/2013\/581631"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.2174\/156802606778194217","article-title":"Anti-TNF-\u03b1 antibody therapies in autoimmune diseases","volume":"6","author":"Chatzantoni","year":"2006","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2147\/BTT.S207246","article-title":"Remicade (R) (infliximab): 20 years of contributions to science and medicine","volume":"13","author":"Melsheimer","year":"2019","journal-title":"Biol. Targets Ther."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Lim, H., Lee, S.H., Lee, H.T., Lee, J.U., Son, J.Y., Shin, W., and Heo, Y.S. (2018). Structural Biology of the TNF alpha Antagonists Used in the Treatment of Rheumatoid Arthritis. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19030768"},{"key":"ref_63","unstructured":"Reddy, S.P., Shah, V.V., Lin, E.J., and Wu, J.J. (2016). Therapy for Severe Psoriasis, Elsevier."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0092-8674(93)90132-A","article-title":"Crystal-Structure of the Soluble Human 55 Kd Tnf Receptor-Human Tnf-Beta Complex\u2014Implications for Tnf Receptor Activation","volume":"73","author":"Banner","year":"1993","journal-title":"Cell"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis\u2014A randomized, controlled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/sj.jidsymp.5650037","article-title":"Mechanisms of action of etanercept in psoriasis","volume":"12","author":"Tan","year":"2007","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00296-014-3080-5","article-title":"Etanercept biosimilars","volume":"35","author":"Azevedo","year":"2015","journal-title":"Rheumatol. Int."},{"key":"ref_68","unstructured":"Brambilla, A., and Simonini, G. (2016). Handbook of Systemic Autoimmune Diseases, Elsevier."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/tcrm.2007.3.1.133","article-title":"Adalimumab in the treatment of arthritis","volume":"3","author":"Mease","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.berh.2004.04.005","article-title":"The treatment of rheumatoid arthritis (Retracted Article. See vol 22, pg AR3, 2008)","volume":"18","author":"Simon","year":"2004","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/ard.61.suppl_2.ii70","article-title":"Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: The initial results of five trials","volume":"61","author":"Rau","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1902\/jop.2014.140194","article-title":"Periodontal and Serum Protein Profiles in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitor Adalimumab","volume":"85","author":"Kobayashi","year":"2014","journal-title":"J. Periodontol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1002\/art.34565","article-title":"Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy","volume":"64","author":"McGovern","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/1744666X.2017.1288097","article-title":"Adalimumab for the treatment of uveitis","volume":"13","author":"LaMattina","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.clinthera.2009.06.015","article-title":"Certolizumab Pegol for the Management of Crohn\u2019s Disease in Adults","volume":"31","author":"Rivkin","year":"2009","journal-title":"Clin. Ther."},{"key":"ref_76","first-page":"37","article-title":"An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: Place in therapy","volume":"8","author":"Rosa","year":"2016","journal-title":"Open Access Rheumatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1345\/aph.1R203","article-title":"Mixed Treatment Comparison of the Treatment Discontinuations of Biologic Disease-Modifying Antirheumatic Drugs in Adults with Rheumatoid Arthritis","volume":"46","author":"Desai","year":"2012","journal-title":"Ann. Pharmacother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1002\/art.23964","article-title":"Certolizumab Pegol Plus Methotrexate Is Significantly More Effective Than Placebo Plus Methotrexate in Active Rheumatoid Arthritis Findings of a Fifty-Two-Week, Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study","volume":"58","author":"Keystone","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Curtis, J.R., Mariette, X., Gaujoux-Viala, C., Blauvelt, A., Kvien, T.K., Sandborn, W.J., Winthrop, K., de Longueville, M., Huybrechs, I., and Bykerk, V.P. (2019). Long-Term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn\u2019s disease: A pooled analysis of 11 317 patients across clinical trials. RMD Open, 5.","DOI":"10.1136\/rmdopen-2019-000942"},{"key":"ref_80","first-page":"151","article-title":"Characterization of golimumab (CNTO 148), a novel fully human monoclonal antibody specific for human TNF\u03b1","volume":"66","author":"Shealy","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4161\/mabs.12304","article-title":"Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor \u03b1","volume":"2","author":"Shealy","year":"2010","journal-title":"mAbs"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2165\/00063030-200923020-00005","article-title":"Golimumab: In the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"23","author":"Oldfield","year":"2009","journal-title":"BioDrugs"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/0091270006298188","article-title":"Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis","volume":"47","author":"Zhou","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4161\/mabs.1.5.9286","article-title":"Golimumab","volume":"1","author":"Mazumdar","year":"2009","journal-title":"mAbs"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1002\/bit.26438","article-title":"Biosimilars: Key regulatory considerations and similarity assessment tools","volume":"114","author":"Kirchhoff","year":"2017","journal-title":"Biotechnol. Bioeng."},{"key":"ref_86","unstructured":"(2021, February 18). FDA-Biosimilar, Available online: https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information."},{"key":"ref_87","unstructured":"McGowan, S., and Jesse, M. (2021). Biosimilars Pipeline Report, AmerisourceBergen."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12967-019-1965-5","article-title":"Identification of novel inhibitors for TNF\u03b1, TNFR1 and TNF\u03b1-TNFR1 complex using pharmacophore-based approaches","volume":"17","author":"Saddala","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"10708","DOI":"10.1038\/s41598-020-67801-0","article-title":"Novel candidate drugs in anti-tumor necrosis factor refractory Crohn\u2019s diseases: In silico study for drug repositioning","volume":"10","author":"Kwak","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jare.2018.09.003","article-title":"Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: Usefulness of administrative data","volume":"15","author":"Quartuccio","year":"2019","journal-title":"J. Adv. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.crohns.2013.01.009","article-title":"Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease","volume":"7","author":"Mocci","year":"2013","journal-title":"J. Crohns Colitis"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Kotyla, P.J. (2018). Bimodal Function of Anti-TNF Treatment: Shall We Be Concerned about Anti-TNF Treatment in Patients with Rheumatoid Arthritis and Heart Failure?. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19061739"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Sartori, N.S., Picon, P., Papke, A., Neyeloff, J.L., and Chakr, R.M.D. (2019). A population-based study of tuberculosis incidence among rheumatic disease patients under anti-TNF treatment. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0224963"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2147\/CEG.S237646","article-title":"Risk of Lymphoma Associated with Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: Implications for Therapy","volume":"13","author":"Dahmus","year":"2020","journal-title":"Clin. Exp. Gastroenter."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1517\/14712598.2011.590798","article-title":"Tumor necrosis factor biologics beyond psoriasis in dermatology","volume":"11","author":"Patel","year":"2011","journal-title":"Expert Opin. Biol. Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/5\/2719\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:34:51Z","timestamp":1760160891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/5\/2719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,8]]},"references-count":95,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["ijms22052719"],"URL":"https:\/\/doi.org\/10.3390\/ijms22052719","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,8]]}}}